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Highlights 
• A method for the quantification of fosfomycin using dried plasma spot sampling.  
• Validated to FDA guidelines and current scientific standards on microsampling. 
• Includes a comparison to gold-standard liquid plasma sampling.  
• Includes data from a critically ill patient in a pilot pharmacokinetic study. 
 
 
Abstract 
Quantification of fosfomycin in the plasma samples of patients is the basis of clinical 
pharmacokinetic studies from which evidence based dosing regimens can be devised to 
maximise antibiotic effectiveness against a pathogen. We have developed and validated a LC-
MS/MS method to quantify fosfomycin using dried plasma spot sampling. Following HILIC 
chromatography, fosfomycin and ethylphosphonic acid, used as internal standard, were 
measured using negative-ion multiple reaction monitoring. 
The method was linear over the calibration range of 5 to 2000 mg/L of fosfomycin. Intra-day 
assay results for dried plasma spot quality control samples at 15.6, 79.9 and 1581 mg/L of 
fosfomycin had precision of ± 4.2, 8.2, and 2.0%, respectively, and accuracy of +3.9, -0.1, and -
1.2%, respectively. Recovery of fosfomycin from dried plasma spots was calculated as 83.6% 
and the dried plasma spot samples were found to be stable stored at room temperature for 
three months and when stored for four hours at 50°C.  A Bland-Altman plot comparing DPS to 
plasma sampling found a negative bias of 16.6%, with all but one sample within the mean limits 
of agreement (-2.6 to 30.6%). Dried plasma spot sampling provides a useful tool for 
pharmacokinetic research of fosfomycin. 
1. Background 
Fosfomycin is a broad-spectrum bactericidal antibiotic with a unique mechanism of action, 
inhibition of phosphoenolpyruvate transferase, the enzyme involved in the synthesis of 
peptidoglycan which is found in the cell wall of Gram-negative and Gram-positive bacteria [1, 
2].  
Fosfomycin is generating substantial interest as an intravenous or enteral therapy for multi-
drug resistant (MDR) pathogens [3, 4]. With an increasing prevalence of MDR bacteria, 
combined with a steadily decreasing number of usable antibiotics available, fosfomycin offers a 
potential infection treatment option for critically-ill patients.  
Critical illness is associated with a significant distortion of pharmacokinetics for many 
antibiotics [5]. Changes in fosfomycin pharmacokinetics can significantly impact concentrations 
at the site of infection, and as such, dose alterations may be required to ensure that optimal 
exposures are achieved [6]. Pharmacokinetic studies can provide evidence based dosing 
regimens and maximise antibiotic effectiveness against a pathogen.   
Dry micro-sampling techniques offer several advantages over the gold-standard of traditional 
liquid plasma sampling for use in clinical pharmacokinetic studies including: low sample 
volumes, simplified collection, as well as a reduction in shipment and storage costs (traditional 
liquid plasma samples require frozen storage and transport).  
However, dry whole-blood micro-sampling techniques, such as dried blood spots, are known to 
exhibit a bias due to hematocrit in quantitative analysis for sub-punched dried blood spots due 
to a non-homogeneous distribution of blood across the spot, viscosity-related diffusion 
properties of blood on dried blood spots, and may influence recovery and matrix effects in LC-
MS applications [7, 8]. Dried plasma spots may therefore be better suited for clinical 
pharmacokinetic studies in critically-ill patients, as these patients can commonly experience 
anaemia and consequently exhibit low levels of hematocrit [9].  
Quantification of drugs using the dried plasma spot sampling technique has been described for 
daptomycin [10], valproic acid and gabapentin [11, 12], linezolid [13], paroxetine[14], 
acetaminophen [15], guanfacine [16], iothalamate [17], vigabatrin [18], triazoles [19], and anti-
epileptic drugs [20], as well as anti-HIV drugs [21]. 
There are several analytical techniques available for the determination of fosfomycin in human 
plasma: using gas chromatography [22, 23], liquid chromatography (LC) - spectrophotometric 
detection [24], LC - photometric detection , capillary zone electrophoresis [25, 26], and, more 
recently, with derivatization and LC - atmospheric pressure chemical ionization mass 
spectrometry [27] and LC – tandem mass spectrometry (MS/MS) [28, 29]. However, no 
methods have been published describing the quantitation of fosfomycin in dried plasma spots. 
The aim of this work was to develop a reliable, quick and sensitive method for the quantitation 
of fosfomycin (structure in Figure 1) using a dried plasma spot (DPS) sampling technique, 
compare it to the gold standard of whole plasma sampling, and assess its suitability for a 
clinical pharmacokinetic study.  
2. Experimental 
2.1. Materials and reagents 
Fosfomycin, ethylphosphonic acid (internal standard), methanol, and acetonitrile (HPLC 
gradient-grade solvent) were purchased from Sigma-Aldrich and ammonium acetate was 
obtained from Ajax Univar. Ultra-pure water was obtained using a four-module Hi-Pure 
Permutit system manufactured by Permutit, Bayswater, Australia. Drug-free human plasma 
was obtained from the Australian Red Cross Blood Service. Whatman (GE Healthcare, 
Maidstone, U.K.) supplied the 903 Sample Collection Paper used for dried plasma spots. 
2.2. Instruments and conditions 
The LC-MS/MS used is a Shimadzu Nexera UHPLC equipped with a Shimadzu 8030+ triple 
quadrupole mass spectrometer (MS) detector. An electro-spray ionization (ESI) source interface 
operating in negative-ion mode was used for the multiple reaction monitoring (MRM) LC-
MS/MS analysis with the compounds were separated on a Merck SeQuant zic-HILIC, 2.1 x 50 
mm, 5.0 μm analytical column. LC and MS conditions for fosfomycin and the internal standard 
have been previously published [29]. The injection volume used was 1.0 μL. The retention time 
for both fosfomycin and ethylphosphonic acid was 2.4 min. 
2.2.1. Standards for dried plasma spot analysis 
Aqueous stock solutions for plasma standard preparation (at 10 000, 20 000 and 50 000 mg/L 
of fosfomycin) were stored at -80°C. These were diluted with drug free plasma to yield ten 
calibration standards from 5 to 2000 mg/L of fosfomcyin, ensuring the aqueous dilution volume 
in each standard was below 5% v/v. The calibration standards were then dispensed (20 µL) 
onto sample collection paper and dried for two hours at room temperature in a Class 2 
Biosafety Cabinet with filtered, circulating air. The calibration standards were then stored in 
sealed plastic bags and processed alongside the clinical samples. 
2.2.2. Internal standard solution 
Ethylphosphonic acid in methanol was used as internal standard for the assay (at 10 mg/L) and 
stored at 4°C.  
2.2.3. Quality control sample preparation 
Quality control samples were prepared by spiking drug free plasma with fosfomycin stock 
solutions, prepared independently of standard solutions, to concentrations of 15, 80 and 1600 
mg/L (ensuring the aqueous dilution volume in each standard was below 5% v/v), dispensed 
(20 µL) onto sample collection paper and dried for two hours at room temperature in a Class 2 
Biosafety Cabinet with filtered, circulating air. The quality control samples were then stored at 
room temperature in sealed plastic bags. 
2.3. Extraction of dried plasma spot samples for LC-MS/MS analysis 
Dried plasma spot samples were extracted by manually punching a 3 mm disc from the centre 
of the DPS and inserting it into a 96-deep well plate containing 200 μL of internal standard 
solution (10 mg/L ethylphosphonic acid in methanol). The 96-deep well plate was capped and 
mixed for 30 minutes at 1200 r.p.m. on a lateral shaker. The dried plasma spot disc was 
removed, the 96-deep well plate re-sealed, vortex mixed for 3 seconds, followed by LC-MS/MS 
analysis. 
2.4. Extraction of liquid plasma samples for LC-MS/MS analysis 
The analysis of plasma samples for LC-MS/MS analysis was performed by protein precipitation 
with acetonitrile and has been published elsewhere [29] and is used here for comparative 
purposes with dried plasma spot clinical samples only.  
2.5. Data analysis 
The concentration of each clinical sample was back-calculated using least squares regression 
analysis based on the peak-area ratio (drug/internal standard area responses) against 
concentration (x) from the calibration curve prepared within the batch. 
2.6. Method of validation 
The validation was performed in accordance with the guidelines provided by the US FDA with 
pre-established acceptance criteria required to demonstrate the method is suitable for the 
intended purpose [30] and current scientific standards on microsampling [31-33]. The 
validation for extraction of fosfomycin from dried plasma spots was assessed for lower limit of 
quantification (LLOQ), linearity, inter-day precision and accuracy, sample spot volume, matrix 
effects, recovery, storage and transport stability.  
2.6.1. Limit of quantification and detection limits 
The LLOQ for fosfomycin was evaluated by analysis of replicate standards (n=5) prepared as 
dried plasma spot samples and subsequently extracted in a single batch. The acceptance 
criteria was established as that the back-calculated concentration results should have precision 
that does not exceed 20% of the CV and accuracy within 20% of the nominal concentration. The 
limit of detection (LOD) for fosfomycin was calculated based on its definition as being the 
lowest peak reliably distinguished from the background noise and calculated as ≥ three-times 
the noise of the blank dried plasma spot sample.  
2.6.2. Linearity 
To investigate linearity, three calibration curves consisting of ten non-zero standards, using the 
concentration range of 5 to 2000 mg/L of fosfomycin in plasma and prepared in different runs 
(n=3) as dried plasma spots. The linearity selected was the simplest calibration model and 
weighting that satisfied the criteria of results being within 20% deviation from the LLOQ and 
within 15% deviation of standards other than the LLOQ, from nominal concentrations. Linear 
regression models were evaluated using a linear and quadratic regression analysis, with 
unweighted and weighted parameters evaluated, including weighting factors of 1/x, 1/x
2
, 1/y, 
1/y
2
. 
2.6.3. Precision and accuracy 
Intra-assay (n=5) precision and accuracy for fosfomycin throughout the calibration range for 
dried plasma spot sampling was evaluated by the analysis of quality control samples at three 
different concentrations, determined against a standard calibration curve in a single batch. 
Inter-assay precision and accuracy was evaluated similarly, for the duplicate analysis of quality 
control samples in two separate batches (n=4). The acceptance criteria was established as that 
the mean value at each concentration should have precision that does not exceed 15% of the 
CV and accuracy within 15% of the nominal concentration.  
2.6.4. Sample spot volume 
The effect of sample spot volume was evaluated for a range of dried plasma spot sampling 
volumes by identifying a trend in fosfomycin concentration across a range of sample spot 
volumes (from 5 to 30 μL), and determining if there was unacceptable variability (>5%) in peak 
area obtained from samples prepared from low volumes (5 μL) to high volumes (30 μL).  
2.6.5. Matrix effects 
Matrix effects were evaluated to identify any suppression or enhancement of signal from an 
interfering substance around the retention time of fosfomycin by using the matrix factor test. 
Dried plasma spot samples were prepared with five different blank matrices and extracted in 
duplicate.  The blank matrix extracts and non-matrix (water) samples were spiked with internal 
standard and low and high concentration levels of fosfomycin and the peak areas measured. 
The precision of the matrix factor (normalized against internal standard, where applicable) was 
used to determine if any concentration level demonstrated unacceptable variability from the 
expected result.  
2.6.6. Recovery 
The recovery of fosfomycin was evaluated by comparing the peak area for triplicate samples 
spiked with fosfomycin in matrix prior to sample preparation, with triplicate samples spiked 
after sample preparation. Care was taken to ensure the injection matrix was identical in 
comparable samples. 
2.6.7. Storage and transport stability 
Stability of fosfomycin stored as dried plasma spot samples at room temperature was assessed 
by comparing the peak area ratio of the dried plasma spot samples stored at room 
temperature for three months to the peak area ratio of freshly prepared dried plasma spot 
samples, with each sample prepared at one concentration and analysis in triplicate. Stability of 
fosfomycin during transport was assessed by comparing the peak area of dried plasma spot 
samples, at two concentrations, stored at 50°C for four hours to the peak area of dried plasma 
spot samples stored at room temperature for four hours, with each sample prepared in 
triplicate. Results for stability were considered acceptable when the % difference of the stored 
sample from the original result was within 15%. 
2.7. Pharmacokinetic application 
The method was developed and validated to determine the suitability of the analysis of 
fosfomycin samples stored as dried plasma spots from a pharmacokinetic clinical trial with 
critically ill patients receiving intravenous fosfomycin for the treatment of an infection in an 
Intensive Care Unit. 
One critically ill patient was administered an intravenous dose of 6 g fosfomycin disodium, 
every eight hours. Blood samples (3 mL) were taken prior to dosing (0 h) and 0.5, 0.75, 1, 1.5, 2, 
4, and 6 h post administration using heparinized vacuum tubes (Greiner Bio-One, Vacuette® 
LiHep) on the second day of fosfomycin administration and on the fifth day of fosfomycin 
dosing. Blood samples were centrifuged at 3000 rpm for 10 min to obtain plasma samples. 
Plasma samples were transferred into 2 mL polypropylene tubes, capped and stored at -80°C. 
On receipt in to the laboratory, and immediately prior to plasma analysis, samples were 
thawed and 20 μL dispensed onto dried plasma spot paper. The dried plasma spot clinical 
samples were then dried for 2 hours at room temperature in a Class 2 Biosafety Cabinet with 
filtered, circulating air. The dried plasma spot clinical samples were then stored in sealed 
plastic bags at room temperature until analysis. 
This clinical procedure was conducted in accordance with the principles laid down by the ICH 
guidelines for Good Clinical Practice and approved by the University of Queensland Medical 
Research Review Committee (clearance # 2012000870) and the Epistimoniko Symvouleio 
(Scientific Committee) of Attikon University Hospital (approval MEΘ-84/13-3-12). 
The samples from the pharmacokinetic profile acquired are used to evaluate the correlation 
between the use of dried plasma spot sampling to the gold-standard sampling technique of 
frozen plasma. Correlation between the two methods was assessed with a Bland Altman plot 
(Figure 2b) using Microsoft® Excel® for Mac 2011, version 14.2.2, with 95% confidence 
intervals reported for the mean and limits of agreement. 
3. Results and discussion 
3.1. Use of dried plasma spot extraction 
The use of dried plasma spot allows a very simple extraction of drug from the proteinaceous 
matrix. The extraction performed in this method was clean and did not require centrifugation 
prior to LC-MS/MS analysis. The LOD and repeatability of LLOQ demonstrate the ability of the 
method to use very small samples - with a sub-punch from a 20 μL sample being used in the 
extraction – and sample volume testing demonstrating it is not necessary to apply precise 
volumes of plasma in order to obtain accurate results. 
While the venous sampling and centrifugation of dried plasma spots is more onerous for staff 
performing than the sampling than dried blood spots, the advantages of transportation, 
storage and simplicity of extraction are still realised relative to traditional liquid plasma 
samples. The use of membrane filtration devices to directly form dried plasma spot samples 
may offer a simplification to preparation [16, 34] and with this the dried plasma spot sampling 
techniques may offer more of the benefits currently available with dried blood spots – smaller 
sample volumes from thumb or needle-prick, no pre-treatment prior to shipment – without the 
inherent challenges of samples containing hematocrit.  
3.2. Validation 
The precision and accuracy (n=5) of the dried plasma spot sample extraction at the LLOQ are 
reported in Table 2, with all five individual accuracy results within 10%. The limit of detection 
(LOD) is defined as being reliably distinguished from the background noise and calculated as ≥ 
three-times the noise of the blank plasma sample. From the validation the LLOQ ratio of signal 
to noise was calculated as 35, and therefore the LOD was estimated as being approximately 0.5 
mg/L for the dried plasma spot sample extraction. 
A linear regression provided the simplest calibration model across the concentration range, and 
the 1/concentration
2
 weighting improved the correlation coefficient considerably. This model 
met the acceptance criteria with the back-calculated concentration results being within 20% 
deviation from the LLOQ and within 15% deviation of standards other than the LLOQ, from 
nominal concentrations, for eight out of ten of the non-zero standards. The calibration range, 
mean correlation coefficient (r
2
) and the percentage of maximum deviation (inaccuracy) of the 
standards of the three calibration curves are presented in Table 1. 
The precision and accuracy of the dried plasma spot sample assay at the prepared QC levels are 
presented in Table 2; the acceptance criteria was met in all cases.  
Sample volume testing demonstrated no trends across a range of sample spot volumes and a 
+1.6% difference in peak area obtained between a sub-punch from a 5 μL sample spot and a 30 
μL sample spot. 
No signal suppression/enhancement was evident for fosfomycin or the internal standard 
(ethylphosphonic acid) for extraction using dried plasma spot samples, from the matrix studies 
performed as evidenced by significant bias or variability. The results of the matrix effect 
evaluations are described in Table 2. 
Validation revealed adequate recoveries for both fosfomycin (83.6%) and ethylphosphonic acid 
(87.1%) from dried plasma spots.  The performance of the method was not adversely affected 
by the less than complete recovery as demonstrated by there being sufficient signal at the 
LLOQ, and acceptable precision and accuracy validation. 
Stability of fosfomycin in plasma when applied to sample collection paper and stored at room 
temperature for 3 months was acceptable with a difference in peak area ratio observed of -
4.9% at 500 mg/L of fosfomycin. Stability of fosfomycin during transport at 50°C for four hours 
was acceptable with a mean difference observed of 0.2%.  
Stock solution stability for fosfomycin has been previously reported as being stable for aqueous 
solutions stored for over 16 months at -80°C and for over 11 months at -20°C; freeze-thaw 
stability in liquid plasma samples has also been previously reported as being stable across three 
freeze-thaw cycles [29]. In-house data on storage of frozen plasma samples containing 
fosfomycin was acceptable with a difference in concentration of 11.6% at -20°C for 20 months.  
3.3. Application 
This method has been successfully applied to samples of a clinical pharmacokinetic study. The 
plasma concentration-time patient profile for one patient is presented in Figure 2. A 58 year 
old male provided samples after receiving his fourth and thirteenth dose of 6 g intravenous 
fosfomycin disodium, every 8 hours. The results of the Bland-Altman plot (Figure 2b) 
demonstrate that the DPS concentrations were subject to a consistant negative bias (16.6%) 
compared to the plasma samples, with the precision from the mean result relatively limited 
(7%). The 95% confidence interval for the mean is -12.9 to -20.4%. All but one sample were 
within the mean limits of agreement (-2.6 to 30.6%). The 95% confidence interval for the upper 
limit of agreement was -9.1 to 3.8%, and for the lower limit of agreement was -37.1 to -24.2%. 
Of the 16 samples analysed the differences between the DPS and plasma concentrations 75% 
were below 20% of the mean result, thereby fulfilling the acceptance criteria of a incurred 
sample reanalysis, criteria which is intended for replicate analysis were the results here are 
from different matrix preparations, different extraction procedures, analysed in small and 
single analytical runs, and separate analytical runs (with whole plasma performed separately to 
the DPS analysis), and prepared from different standard solution preparations.  
4. Conclusion 
The method presented here offers a validated quantitative analysis of fosfomycin using a dried 
plasma spot sampling technique.  The assay performance is accurate and precise, with 
sufficiently sensitivity and range of calibration for a clinical pharmacokinetic study.  The dried 
plasma spot sampling technique has advantages over traditional plasma sampling in terms of 
storage temperature, transport and simplicity of sample preparation.  The results of the dried 
plasma spot samples from a clinical pharmacokinetic study were subject to a negative bias of 
16.6%. Of the 16 samples analysed the differences between the DPS and plasma 
concentrations 75% were below 20%, thereby fulfilling the acceptance criteria of a incurred 
sample reanalysis. This method has been demonstrated to be suitable for clinical 
pharmacokinetic study applications for fosfomycin and may provide greater opportunities for 
collaborative research in critically ill populations, including, burns or obese patients. 
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Table 1: Linearity Analysis 
Sample Calibration range  Correlation coefficient * Maximum deviation (%)** 
dried plasma spot 5 to 2000 mg/L 0.9983 7.6 
*Mean (n = 3) 
** Reported maximum deviation from nominal (%) across all standard curves and concentration levels 
 
Table 2: Intra-assay and inter-assay precision and accuracy, matrix, recovery and stability 
studies 
Study Concentration (mg /L) Sample # Mean Accuracy (%) Precision (%) 
LLOQ 5 5 4.96 -0.8 ±6.3 
15 5 15.6 +3.9 ±4.2 
80 5 79.9 -0.1 ±8.2 
Intra-assay 
Precision & 
Accuracy 
1600 5 1581 -1.2 ±2.0 
15 4 15.7 +4.3 ±9.0 
80 4 77.8 -2.8 ±5.2 
Inter-assay 
Precision & 
Accuracy 
1600 4 1632 +2.0 ±2.3 
50 5 1.00
a
  ±0.8 Matrix 
500 5 1.02
a
  ±2.7 
Recovery 500 3 83.6%  ±4.7 
Stability RT
b
 500 3  -4.9 loss  
Stability Trans
c
 500 3  0.2 increase  
a
 matrix factor: calculated as a ratio of peak area of analyte in the presence of matrix to the peak area in the 
absence of matrix (normalized using the internal standard). 
b
 stability at room temperature: calculated as a ratio of peak area analyte to internal standard compared over 
three months of storage as a dried plasma spot sample. 
c
 stability during transport at 50°C: calculated as a ratio of peak area analyte to internal standard compared to 4 
hours of storage as a dried plasma spot sample  
 
Figure 1: Structure of fosfomycin (FOM, left) and the internal standard, ethylphosphonic acid 
(EPA, right),[35,36]. 
 
 
 
 
 
 
 
 
 
  
Figure 2(a): Plasma concentration – time profiles of fosfomycin in a critically ill patient receiving a 6 g fosfomycin 
IV dose every 6 hours, for the second and fifth doses, prepared using an extraction from plasma (diamond, full-
line) and dried plasma spots (DPS, squares, dotted line); 2(b): Bland-Altman plot between plasma and DPS samples 
obtained for fosfomycin (FOM) concentrations from a critically-ill patient. The mean difference demonstrated a 
negative bias of 16.6%, with all but one sample within the mean limits of agreement (-2.6 to 30.6%). 
